Skip to content

To investigate the regulatory mechanism of Mycoplasma pneumoniae resistance gene mutation on inflammatory response

To investigate the regulatory mechanism of Mycoplasma pneumoniae resistance gene mutation on inflammation based on TLR-2/MyD88/NF-?B pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111863
Enrollment
Unknown
Registered
2025-11-06
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycoplasma pneumoniae pneumoniae

Interventions

Observation group:None

Sponsors

Changsha Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Diagnostic criteria for hospitalized children diagnosed with MP pneumonia in our hospital: the diagnostic criteria for community-acquired pneumonia refer to the 8th edition of Zhufutang Practical Pediatrics, and the diagnostic criteria for MPP refer to the guidelines for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023 edition) [1]: On the basis of diagnosis of community-acquired pneumonia, if there is any one of the following two items, (1) single serum MP antibody titer= 1:160 (PA method); (2) During the course of the disease, the double serum MP antibody titer increased by 4 times or more. (2) MP-DNA or RNA positive.

Exclusion criteria

Exclusion criteria: 1. With viruses, bacteria, chlamydia and other mixed infections; 2.Treatment with glucocorticoids and immunosuppressants in the past 3 months before enrollment; 3.Combined with immune diseases or a history of immune diseases; 4.Combined with allergic diseases such as allergic purpura; 5.Combined with bronchial asthma, tuberculosis and other respiratory diseases; 6.History of malignant tumors.

Design outcomes

Primary

MeasureTime frame
Related gene expression: TLR-2, MyD88, and NF-?B;Cytokine levels: IL-6, IL-8, TNF-a;

Countries

China

Contacts

Public ContactLiu Xiaoyan

Changsha Central Hospital

xy.liu1982@163.com+86 731 85667806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026